Get the Stockscreener App
10.03
1.52%
0.15
After Hours:
10.20
0.17
+1.69%
Vir Biotechnology Inc stock is traded at $10.03, with a volume of 7.49M.
It is up +1.52% in the last 24 hours and up +6.93% over the past month.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
See More
Previous Close:
$9.88
Open:
$9.89
24h Volume:
7.49M
Relative Volume:
3.92
Market Cap:
$1.69B
Revenue:
$68.56M
Net Income/Loss:
$-437.99M
P/E Ratio:
-3.1701
EPS:
-3.1639
Net Cash Flow:
$-396.61M
1W Performance:
+9.50%
1M Performance:
+6.93%
6M Performance:
+67.17%
1Y Performance:
+88.89%
1-Day Range:
$9.875
$10.32
1-Week Range:
$9.16
$10.38
52-Week Range:
$4.155
$11.66
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
10.03 | 1.67B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 121.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 65.01B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.26B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 39.14B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 37.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-03-25 | Initiated | Evercore ISI | Outperform |
| Aug-27-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
Enterprise value to EBIT forward of Vir Biotechnology, Inc. – NASDAQ:VIR - TradingView
Price to sales forward of Vir Biotechnology, Inc. – NASDAQ:VIR - TradingView
Enterprise value to revenue forward of Vir Biotechnology, Inc. – NASDAQ:VIR - TradingView
Vir Biotechnology, Inc. Actuals & Estimates (NASDAQ:VIR) - TradingView
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
VIR Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Vir Biotechnology Inc (VIR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vir Biotechnology Inc (VIR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biotech executives convene under Vir Biotechnology leadership to drive innovation at BIO2026 - Traders Union
Vir Biotechnology (NASDAQ:VIR) Draws Attention Amid Pipeline Focus - Kalkine Media
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership - Stocktwits
Vir Biotechnology Inc (VIR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vir Biotechnology Inc (VIR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vir Biotechnology Inc (VIR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vir Biotechnology Inc (VIR) Institutional Confidence - TradingKey
Vir Biotechnology Inc (VIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vir Biotechnology Inc (VIR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million - AOL.com
VIR Should I Buy - Intellectia AI
VIR Maintained by Morgan Stanley -- Price Target Raised to $27 - GuruFocus
Morgan Stanley Raises Vir Biotechnology (NASDAQ:VIR) Price Target to $27.00 - MarketBeat
Vir Biotechnology, Inc. Stock 12‑Month Price Target Raised to $21.56, Implies 161% Upside - TradingView
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors - BioSpace
Vir Biotechnology (VIR) director awarded RSUs and stock options in new grants - Stock Titan
Vir Biotechnology (VIR) director Coughlin reports zero share ownership - Stock Titan
Vir Biotechnology Adds Timothy Coughlin to Board, Audit Chair - TipRanks
Vir Biotechnology appoints Timothy Coughlin to board - Investing.com UK
Vir Biotechnology appoints Timothy Coughlin to board By Investing.com - Investing.com South Africa
Vir Biotechnology (VIR) appoints Timothy Coughlin as director and Audit Committee chair - Stock Titan
WINTON GROUP Ltd Buys 131,555 Shares of Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology: Analyzing the Bullish Thesis on VIR-5500 and mCRPC OpportunityAnalyst Coverage Count - newsline.com
VIR News | VIR BIOTECHNOLOGY INC (NASDAQ:VIR) - ChartMill
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now? - Insider Monkey
Earnings call transcript: Vir Biotech reports larger-than-expected Q1 2026 loss - Investing.com
Vir Biotech Q1 2026 presentation: $2.2B partnerships fuel oncology pivot - Investing.com
VIR Maintained by Leerink Partners -- Price Target Raised to $21 - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $21.00 - MarketBeat
Insider Sell: Brent Sabatini Sells Shares of Vir Biotechnology I - GuruFocus
Insider Sell: Janet Napolitano Sells 3,200 Shares of Vir Biotech - GuruFocus
Vir Biotechnology director Janet Napolitano sells $30,239 in stock - Investing.com UK
Vir Biotechnology director Janet Napolitano sells $30,239 in stock By Investing.com - Investing.com India
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):